Search PubMed⌕ Search

Biomedical subjects

David C Klonoff

Publications and source records attributed to David C Klonoff.

15 recordsLinked to original sources
PubMed2004

An adaptive drug infusion system.

BACKGROUND: In order to reduce the overall size and power consumption of ambulatory drug infusion systems, and to provide higher delivery accuracy, faster start-up, and more rapid occlusion detection, a non-contacting, low-power thermal time-of-flight technology has been used to provide a pressure-based miniature wearable drug infusion system that automatically compensates in real time for changes in pressure, viscosity, and flow path geometry. METHODS: Prototypes have been designed, built, and tested on the bench and on animals. RESULTS: For liquid volumes ranging from 30 nL to 100 microL, the measured accuracy and precision of delivery were better than 1%. Tests on 30-kg swine showed delivery within the study accuracy. CONCLUSIONS: The performance of the prototypes demonstrates that real-time compensation of flow variables provides significant performance improvements in therapeutic infusion.

Equipment Design↗
PubMed2003

Technological advances in the treatment of diabetes mellitus: better bioengineering begets benefits in glucose measurement, the artificial pancreas, and insulin delivery.

The management of type 1 diabetes is being advanced by innovations in glucose measurement, development of an artificial pancreas, and in alternate routes of insulin delivery. Emerging technologies will allow insulin to be delivered more effectively. In the future, patients with type 1 diabetes will receive insulin in optimal quantities (because of more information about blood glucose values) at optimal times (because of better integration of blood glucose values with appropriate insulin dosages) by way of optimal routes into the body (because of needle-free routes of administration) in order to achieve optimal blood glucose control. Emerging technologies for improved care of patients with type 1 diabetes include: 1. new methods for monitoring glucose, including noninvasive, minimally invasive, continuous, and alternate site measurement technologies; 2. new methods for integrating glucose values and insulin dosages, known as the artificial pancreas; and 3. new routes of insulin administration, including inhaled, oral, buccal, nasal, and transdermal drug delivery systems. These new technologies will facilitate proper treatment of type 1 diabetes and improve the lives of affected patients.

Biomedical Engineering↗